UroGen Pharma

Company Overview

Snapshot

Founded in April 2004, UroGen Pharma operates with 201–500 employees. The company has raised over $522.2 million across 11 funding rounds from 8 investors. In March 2026, UroGen refinanced its debt with a $250 million facility.

Business overview

UroGen Pharma is a biotech company focused on developing novel solutions for specialty cancers and urologic diseases. The company utilizes its proprietary RTGel, a sustained-release, hydrogel-based platform technology, to enhance the therapeutic profiles of existing drugs by enabling longer exposure of the urinary tract tissue to medications. UroGen's lead product candidates, UGN-101 and UGN-102, are designed for non-surgical tumor removal and treatment of non-muscle-invasive urothelial cancer, serving the pharmaceuticals and healthcare sectors.

Strategic signal

In October 2024, UroGen Pharma announced the FDA's acceptance of its New Drug Application for UGN-102, a significant regulatory milestone that validates the potential of its non-surgical treatment for bladder cancer. This development signals a strong progression towards commercialization and addresses a critical unmet need in the urologic oncology market, indicating potential for substantial market entry and revenue growth.

Company Intelligence Q&A

What was a significant recent financial event for UroGen Pharma?

In March 2026, UroGen Pharma refinanced its debt with a $250 million facility at an 8.25% rate, according to a report on Investing.com.

What is the status of UGN-102 for bladder cancer treatment?

In October 2024, the FDA accepted UroGen Pharma's New Drug Application for UGN-102 for bladder cancer treatment. This follows the company's announcement in October 2023 of a rolling NDA submission for UGN-102 to begin in January 2024.

What was the outcome of the ENVISION Trial for UGN-102?

In October 2024, results from the ENVISION Trial were published in the Journal of Urology, reporting an 82.3% duration of response 12 months after achieving complete response for UGN-102, positioning it as a potentially first FDA-approved non-surgical treatment for LG-IR-NMIBC.

When did UroGen Pharma appoint a new Chief Financial Officer?

In October 2024, UroGen Pharma appointed Chris Degnan as its Chief Financial Officer.

What is the latest update on UGN-103 clinical trials?

In October 2024, UroGen Pharma dosed the first patient in its Phase 3 clinical trial of UGN-103, a next-generation mitomycin-based formulation for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer.